ClinicalTrials.Veeva
Menu

Find clinical trials for Alzheimer's Disease in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Mental Disorders
Brain Diseases
Nervous System Diseases
Neurocognitive Disorders

Alzheimer's Disease trials near Toronto, ON, CAN:

ExAblate Blood-Brain Barrier Opening for Treatment of Alzheimer's Disease

the safety and efficacy of the ExAblate® Model 4000 Type 2.0 system as a tool to open the blood-brain barrier (BBB) in patients with probable Alzheimer's...

Enrolling
Alzheimer Disease
Device: Blood Brain Barrier (BBB) Disruption
InSightec
InSightec

Toronto, Ontario, Canada

efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...

Enrolling
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Solanezumab
Drug: E2814

Phase 2, Phase 3

The Washington University
The Washington University

Toronto, Ontario, Canada and 37 other locations

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...

Active, not recruiting
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Lecanemab
Drug: Matching Placebo (E2814)

Phase 2, Phase 3

The Washington University
The Washington University

Toronto, Ontario, Canada and 37 other locations

progression of AD, as compared to no stimulation (OFF), by measuring baseline (pre-implantation) to 12-month change in the integrated Alzheimer's...

Active, not recruiting
Alzheimer Disease
Device: DBS-f On
Device: DBS Off
Functional Neuromodulation

Toronto, Ontario, Canada and 20 other locations

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

Toronto, Ontario, Canada and 116 other locations

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's...

Active, not recruiting
Alzheimer Disease
Drug: LY3372689
Drug: Placebo

Phase 2

Lilly
Lilly

Toronto, Ontario, Canada and 68 other locations

versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Other: Placebo
Biological: Bepranemab

Phase 2

UCB
UCB

Toronto, Canada and 101 other locations

be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...

Active, not recruiting
Alzheimer's Disease
Drug: Lecanemab 2.5 mg/kg
Drug: Lecanemab 10 mg/kg

Phase 2

Eisai
Eisai

Toronto, Ontario, Canada and 168 other locations

administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's...

Enrolling
Alzheimer Disease
Drug: ACU193
Drug: Placebo

Phase 2, Phase 3

Acumen Pharmaceuticals

Toronto, Ontario, Canada and 111 other locations

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...

Active, not recruiting
Early Alzheimer's Disease
Drug: Placebo
Drug: Lecanemab

Phase 3

Eisai
Eisai

Toronto, Ontario, Canada and 246 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems